Loading
Led the ZUMA-7 trial that put CAR-T ahead of transplant in relapsed large B-cell lymphoma.
Frederick L. Locke is Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. He is known for leading the ZUMA-7 trial, which put CAR-T ahead of transplant in relapsed large B-cell lymphoma, and was principal investigator of ZUMA-1 and ZUMA-7 with axicabtagene ciloleucel. His selected paper reports axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. He is also a leader in CAR-T real-world outcomes and in managing the toxicity of cellular therapy.
| Title | Journal | Year |
|---|---|---|
| Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma | New England Journal of Medicine | 2022 |
| ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma | New England Journal of Medicine | 2017 |
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
ZUMA-1 showed that CAR-T can cure a meaningful fraction of adults whose aggressive lymphoma no longer responds to chemotherapy, a group with a historical median survival of about six months (SCHOLAR-1). Axi-cel became the first CAR-T approved for lymphoma and later the first to beat standard second-line therapy in ZUMA-7. The comparatively high neurotoxicity of CD28-costimulated products was also first characterised here.
Shares ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, Axicabtagene ciloleucel, CD19.
Shares ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, ZUMA-7, Axicabtagene ciloleucel, CD19.
Shares ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma, Axicabtagene ciloleucel, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares CD19, CAR-T cell therapy, Diffuse large B-cell lymphoma.
Shares ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, CD19, CAR-T cell therapy.